The global market for microneedle drug delivery devices expected to reach $8.9 billion by 2029, expanding at a CAGR of 7.7% over the forecast period, driven by increasing preference for minimally invasive and pain-free drug administration, early onset of action, increased permeability and efficacy, better patient compliance, and easy access to self-administration.
- In addition, the major factors driving market growth include rising cases of metabolic and infectious diseases, technological advancements, improving healthcare infrastructure and wider range of microneedle drug delivery applications worldwide.
Microneedles (MNs) are non-invasive and are associated with significantly less or no pain at the site of administration to the skin. MNs are excellent in delivering both small and large molecules to the patients. Microneedles are fabricated using a microelectromechanical system employing silicon, metals, polymers or polysaccharides. In addition to improving therapeutic benefits, microneedles provide very precise and consistent results with low inter-subject variability in bioavailability. Microneedles can be used to deliver macromolecules such as insulin, growth hormones, immunobiologicals, proteins and peptides. MN technology is a mode of active transdermal drug delivery and is intended to be used a as a replacement to the traditional syringe injections. However, there remain challenges with sustained delivery, efficacy, cost-effective fabrication, and large-scale manufacturing.
- Advances in microneedle research led to development of dissolvable/degradable and hollow microneedles to deliver drugs at a higher dose and to engineer drug release. Microneedles containing ‘cosmeceuticals’ are currently available to treat acne, pigmentation, scars and wrinkles, as well as for skin tone improvement.
- The microneedle drug delivery systems have the potential to increase drug efficacy by improving drug absorption and target-specific drug administration. This reduces the quantity of drugs needed to achieve therapeutic effects, potentially reducing healthcare costs and minimizing side effects.
- Additionally, several microneedles -based products are undergoing clinical trials to evaluate its safety, efficacy, and tolerability.
- The microneedle drug delivery systems have the potential to increase drug efficacy by improving drug absorption and target-specific drug administration. This reduces the quantity of drugs needed to achieve therapeutic effects, potentially reducing healthcare costs and minimizing side effects.
The global market for microneedle drug delivery devices research report provides market size ($million 2019 to 2029), market share analysis, growth trends and forecast (CAGR%, 2023 to 2029).
The global market for microneedle drug delivery devices segmented by product (solid, hollow, dissolving, coated, others), material (silicon, metal, polymer, others), application (dermatology, drug delivery, pain management, cancer therapy, vaccine delivery, others), and geography.
- Based on the products, the hollow-shaped microneedle devices segment accounted for the largest share of the total microneedle-based drug delivery systems market. A variety of materials such as silicon, stainless steel, and polymers have been used to fabricate solid, coated, hollow, or dissolvable microneedles.
- Hollow microneedles are commonly used to deliver vaccines and hormones, such as insulin for diabetic patients. Compared to the solid microneedle, the hollow microneedle can handle a large dose/amount of drug solution.
- Additionally, it controls the drug release over time which makes it suitable for use with liquid vaccine formulations.
- On the other hand, the dissolving or biodegradable microneedles segment expected to expand at the fastest growth rate throughout the forecast period. The dissolvable MN include facilitating the rapid release of macromolecules, and a one-step drug application which promulgates the ease of drug administration. Iontophoresis, sonophoresis and electrophoresis can be used to modify drug delivery when used in concern with hollow microneedles.
- Hollow microneedles are commonly used to deliver vaccines and hormones, such as insulin for diabetic patients. Compared to the solid microneedle, the hollow microneedle can handle a large dose/amount of drug solution.
- Among the materials used for manufacturing microneedles, the metal-based microneedles segment registered the largest revenue share of the global MN-based drug delivery devices market, while the silicon-based microneedles segment predicted to witness the fastest growth rate during the next few years.
- A variety of materials have been used to fabricate different types of MNs. Examples of these materials are silicon, metals, ceramic, and polymers. A combination of different material types has been utilized for biomedical applications in the area of delivery drugs, tissue engineering, and biomedical implants.
- Metals are utilized in the manufacture of MNs as they have good biocompatibility and mechanical properties. Metals have high fracture toughness and yield strength values. Compared to silicon, metals are stronger and harder to break. The first metal utilized in the fabrication of a MN was stainless steel followed by titanium.
- On the other hand, the silicon material possesses numerous advantages over other materials, including its innate flexibility, which allows for easy manufacturability in terms of desirable shapes and sizes of MNs. Silicon has been used to fabricate solid, hollow, and coated MNs.
- In terms of applications, the drug delivery segment dominated the global microneedle drug delivery devices market, whereas the cancer therapy segment anticipated to grow at the fastest rate in the coming years.
- Dosage loading and metering accuracy of microneedles is an important aspect while administering sensitive drugs such as insulin and chemotherapeutics.
- Cancer is the leading cause of death, acting as a global burden, severely impacting the patients’ quality of life and affecting the world economy despite the expansion of cumulative advances in oncology. In cancer treatment, the drug performance could be significantly enhanced by delivering it in the right quantity, at right time and at right site.
- This can be achieved using microneedles, popularly considered as a synergistic combination of transdermal patch with hypodermic needles, wherein a drug is delivered directly to the tumor site via the micro-channels formed by MNs after piercing the SC of the skin. The microneedles are simple, non-invasive, and safer alternatives to the hypodermic needles and syringes.
The global market for microneedle drug delivery systems research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.
In addition, the global market for microneedle drug delivery devices report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major competitors operating in the global market for microneedle drug delivery systems and profiled in this report include 3M Health Care, B. Braun Group, Becton Dickinson and Company, Cardinal Health, Inc., ICU Medical, Inc. (Smiths Medical, Inc.), NanoPass Technologies Ltd., Novartis AG, Raphas Co., Ltd., and Terumo Corporation.
- Product
- Solid
- Hollow
- Dissolving
- Coated
- Others
- Material
- Silicon
- Metal
- Polymer
- Others
- Application
- Dermatology
- Drug Delivery
- Pain Management
- Cancer Therapy
- Vaccine Delivery
- Others
- Geography
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- 3M Health Care
- B. Braun Group
- Becton Dickinson and Company
- Cardinal Health, Inc.
- ICU Medical, Inc. (Smiths Medical, Inc.)
- NanoPass Technologies Ltd.
- Novartis AG
- Raphas Co., Ltd.
- Terumo Corporation
To request Table of Contents and Sample Pages of this report:
https://www.ihealthcareanalyst.com/report/microneedle-drug-delivery-systems-market/
Related publications:
